CR8426A - Anticuerpo del receptor anti-igf-i - Google Patents

Anticuerpo del receptor anti-igf-i

Info

Publication number
CR8426A
CR8426A CR8426A CR8426A CR8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A
Authority
CR
Costa Rica
Prior art keywords
antibodies
igf
cancer
receptor
elevated levels
Prior art date
Application number
CR8426A
Other languages
English (en)
Spanish (es)
Inventor
Singh Rajeeva
J Tavares Daniel
E Dagdigian Nancy
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of CR8426A publication Critical patent/CR8426A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CR8426A 2003-12-08 2006-06-01 Anticuerpo del receptor anti-igf-i CR8426A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody

Publications (1)

Publication Number Publication Date
CR8426A true CR8426A (es) 2007-12-04

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8426A CR8426A (es) 2003-12-08 2006-06-01 Anticuerpo del receptor anti-igf-i

Country Status (13)

Country Link
EP (1) EP1692176A4 (de)
JP (1) JP2008502589A (de)
KR (1) KR20070001883A (de)
CN (1) CN1886424A (de)
AU (1) AU2004303792A1 (de)
BR (1) BRPI0417406A (de)
CA (1) CA2548065A1 (de)
CR (1) CR8426A (de)
EA (1) EA009807B1 (de)
EC (1) ECSP066595A (de)
IL (1) IL174770A0 (de)
MX (1) MXPA06005540A (de)
NO (1) NO20063155L (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190067275A (ko) 2009-12-21 2019-06-14 제넨테크, 인크. 항체 제제
RU2012153241A (ru) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
US9051561B2 (en) 2011-10-10 2015-06-09 Children's Hospital Los Angeles Asparaginase and treating diseases associated with asparagine dependence
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
CA3056573A1 (en) * 2017-05-30 2018-12-06 Teijin Pharma Limited Anti-igf-i receptor antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532685A (ja) * 1998-12-04 2002-10-02 ノバルティス アクチエンゲゼルシャフト 活性化ビトロネクチンレセプターαＶβ３をターゲティングするために有用な方法および組成物
EP1399483B1 (de) * 2001-01-05 2010-04-14 Pfizer Inc. Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
KR20050109489A (ko) * 2003-02-13 2005-11-21 화이자 프로덕츠 인크. 항-인슐린양 성장인자 ｉ 수용체 항체의 용도

Also Published As

Publication number Publication date
AU2004303792A1 (en) 2005-07-07
CA2548065A1 (en) 2005-07-07
KR20070001883A (ko) 2007-01-04
ECSP066595A (es) 2006-10-17
CN1886424A (zh) 2006-12-27
NO20063155L (no) 2006-08-11
EP1692176A1 (de) 2006-08-23
IL174770A0 (en) 2006-08-20
EP1692176A4 (de) 2008-11-12
EA009807B1 (ru) 2008-04-28
MXPA06005540A (es) 2006-08-17
EA200600931A1 (ru) 2006-10-27
JP2008502589A (ja) 2008-01-31
BRPI0417406A (pt) 2007-04-03

Similar Documents

Publication Publication Date Title
SG141243A1 (en) Anti-igf-i receptor antibody
AR061911A1 (es) Anticuerpo antagonista para el tratamiento del cancer
PE20080663A1 (es) Terapia tumoral con una combinacion de anticuerpos anti-her2
ES2571235T3 (es) Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
CR8426A (es) Anticuerpo del receptor anti-igf-i
UA94388C2 (ru) Антиинтегриновый иммуноконьюгат и способы лечения с его помощью
AR070862A1 (es) Terapia de combinacion con antagonistas de c- met y her
AR061245A1 (es) Composiciones y metodos para la modulacion del desarrollo vascular
UA99608C2 (en) PDGFRb-SPECIFIC INHIBITORS
PT2326665E (pt) Proteínas de fusão não citotóxicas compreendendo muteínas de egf
DOP2013000045A (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
AR054254A1 (es) Terapia adyuvante con trastuzumab (herceptin registrado)
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
MX2020009463A (es) Receptor de antígeno quimérico de receptor de il-13 alfa 2 (il13ra2) para inmunoterapia de células t específica para tumor.
NZ599707A (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
WO2007100640A3 (en) Growth hormone receptor antagonist cancer treatment
EA200601405A1 (ru) Гуманизированное антитело
MX2021011750A (es) Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos.
SG171674A1 (en) Methods of treating cancer by administering human il-18 combinations
CO6331345A2 (es) Composiciones y métodos que proporcionan una línea celular de hibridoma depositada como no. de acceso atcc pta-9387 y un anticuerpo producido por esta línea celular de hibridoma
Heller et al. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer
MD2849G2 (ro) Metodă de tratament al cancerului mamar la pacientele de vârstă înaintată
JP2018516230A5 (de)
Sandomenico 3D1, a novel anti-nodal monoclonal antibody to target melanoma
DOP2009000003A (es) Anticuerpo antagonista para el tratamiento del cancer

Legal Events

Date Code Title Description
FC Refusal